Skip to main content
Erschienen in: International Journal of Hematology 3/2023

19.03.2023 | Case Report

First reported case of splenic diffuse red pulp small B-cell lymphoma with novel mutations in CXCR4 and TRAF3 genes

verfasst von: Suying Zheng, Ling Lin, Jing Jin, Fang Liu, Jianguo Wei, Yi Feng, Yaping Zhang, Hongqiang Luo, Jiayue Qin, Weiying Feng

Erschienen in: International Journal of Hematology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is a rare B-cell tumor whose genetic characteristics are poorly understood. Here, we introduce the case of a 62-year-old patient with SDRPL who showed progressive elevation of lymphocytes and progressive spleen enlargement. Immunohistochemistry showed that CD20 and CD79a were positive, and the Ki-67 labelling index was approximately 5%, consistent with the pathological features of splenic B-cell lymphoma. Spleen tissue and peripheral blood samples from the patient were sequenced using a next-generation sequencing platform, and mutations possibly were detected in the CXCR4 and TRAF3 genes that may be related to the pathogenesis of the disease. This finding may provide insights into the molecular pathogenesis of SDRPL and assist in molecular diagnosis and targeted therapy for SDRPL.
Literatur
1.
Zurück zum Zitat Vig T, Kodiatte TA, Manipadam MT, Aboobacker FN. A rare case of splenic diffuse red pulp small B-cell lymphoma (SDRPL): a review of the literature on primary splenic lymphoma with hairy cells. Blood Res. 2018;53(1):74–8.CrossRefPubMedPubMedCentral Vig T, Kodiatte TA, Manipadam MT, Aboobacker FN. A rare case of splenic diffuse red pulp small B-cell lymphoma (SDRPL): a review of the literature on primary splenic lymphoma with hairy cells. Blood Res. 2018;53(1):74–8.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat International Agency for Research on Cancer; World Health Organization. WHO Classification of Tumours of Haematopoieticand Lymphoid Tissues; International Agency for Research on Cancer: Lyon, France, 2008. International Agency for Research on Cancer; World Health Organization. WHO Classification of Tumours of Haematopoieticand Lymphoid Tissues; International Agency for Research on Cancer: Lyon, France, 2008.
3.
Zurück zum Zitat Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48.
4.
Zurück zum Zitat Wang RC, Medeiros LJ, Chang KC. Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration. Int J Hematol. 2019;109(2):133–4.CrossRefPubMed Wang RC, Medeiros LJ, Chang KC. Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration. Int J Hematol. 2019;109(2):133–4.CrossRefPubMed
5.
Zurück zum Zitat Kerbauy MN, Fernandes CM, Bezerra ED, Lage LA, Siqueira SA, Pereira J. Splenic diffuse red-pulp small B-cell lymphoma associated with hepatitis B virus: a report of two cases. Sao Paulo Med J. 2016;134(4):359–65.CrossRefPubMed Kerbauy MN, Fernandes CM, Bezerra ED, Lage LA, Siqueira SA, Pereira J. Splenic diffuse red-pulp small B-cell lymphoma associated with hepatitis B virus: a report of two cases. Sao Paulo Med J. 2016;134(4):359–65.CrossRefPubMed
6.
Zurück zum Zitat Julhakyan HL, Al-Radi LS, Moiseeva TN, Danishyan KI, Kovrigina AM, Glebova SM, et al. A single-center experience in splenic diffuse red pulp lymphoma diagnosis. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S166–9.CrossRefPubMed Julhakyan HL, Al-Radi LS, Moiseeva TN, Danishyan KI, Kovrigina AM, Glebova SM, et al. A single-center experience in splenic diffuse red pulp lymphoma diagnosis. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S166–9.CrossRefPubMed
7.
Zurück zum Zitat Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica. 2010;95(7):1122–9.CrossRefPubMedPubMedCentral Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica. 2010;95(7):1122–9.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Suzuki T, Miyoshi H, Shimono J, Kawamoto K, Arakawa F, Furuta T, et al. Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. Pathol Int. 2020;70(5):280–6.CrossRefPubMed Suzuki T, Miyoshi H, Shimono J, Kawamoto K, Arakawa F, Furuta T, et al. Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. Pathol Int. 2020;70(5):280–6.CrossRefPubMed
10.
Zurück zum Zitat Mendes LS, Attygalle A, Matutes E, Wotherspoon A. Annexin A1 expression in a splenic diffuse red pulp small B-cell lymphoma: report of the first case. Histopathology. 2013;63(4):590–3.PubMed Mendes LS, Attygalle A, Matutes E, Wotherspoon A. Annexin A1 expression in a splenic diffuse red pulp small B-cell lymphoma: report of the first case. Histopathology. 2013;63(4):590–3.PubMed
11.
Zurück zum Zitat Ben Younes K, Doghri R, Mrad K, Ben Romdhane N, Ben A-F. Cyclin A2 as a potential differential marker of splenic diffuse red pulp small B-cell lymphoma: a report of the first case. Ann Hematol. 2017;96(3):511–2.CrossRefPubMed Ben Younes K, Doghri R, Mrad K, Ben Romdhane N, Ben A-F. Cyclin A2 as a potential differential marker of splenic diffuse red pulp small B-cell lymphoma: a report of the first case. Ann Hematol. 2017;96(3):511–2.CrossRefPubMed
12.
Zurück zum Zitat Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, et al. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017;102(10):1758–66.CrossRefPubMedPubMedCentral Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, et al. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017;102(10):1758–66.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Curiel-Olmo S, Mondéjar R, Almaraz C, Mollejo M, Cereceda L, Marès R, et al. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood. 2017;129(8):1042–5.CrossRefPubMed Curiel-Olmo S, Mondéjar R, Almaraz C, Mollejo M, Cereceda L, Marès R, et al. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood. 2017;129(8):1042–5.CrossRefPubMed
14.
Zurück zum Zitat Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med. 2012;13(71):253–65.PubMed Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med. 2012;13(71):253–65.PubMed
15.
Zurück zum Zitat Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, et al. NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol. 2016;40(2):192–201.CrossRefPubMed Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, et al. NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. Am J Surg Pathol. 2016;40(2):192–201.CrossRefPubMed
16.
Zurück zum Zitat Milanesi S, Locati M, Borroni EM. Aberrant CXCR4 signaling at crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia. Int J Mol Sci. 2020;21(16):5696.CrossRefPubMedPubMedCentral Milanesi S, Locati M, Borroni EM. Aberrant CXCR4 signaling at crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia. Int J Mol Sci. 2020;21(16):5696.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Mousavi A. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett. 2020;217:91–115.CrossRefPubMed Mousavi A. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett. 2020;217:91–115.CrossRefPubMed
19.
Zurück zum Zitat Bidkhori HR, Bahrami AR, Farshchian M, Heirani-Tabasi A, Mirahmadi M, Hasanzadeh H, et al. Mesenchymal stem/stromal cells overexpressing CXCR4R334X revealed enhanced migration: a lesson learned from the pathogenesis of WHIM syndrome. Cell Transplant. 2021;30:9636897211054498.CrossRefPubMed Bidkhori HR, Bahrami AR, Farshchian M, Heirani-Tabasi A, Mirahmadi M, Hasanzadeh H, et al. Mesenchymal stem/stromal cells overexpressing CXCR4R334X revealed enhanced migration: a lesson learned from the pathogenesis of WHIM syndrome. Cell Transplant. 2021;30:9636897211054498.CrossRefPubMed
20.
Zurück zum Zitat Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges. Leukemia. 2021;35(2):333–45.CrossRefPubMed Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges. Leukemia. 2021;35(2):333–45.CrossRefPubMed
21.
Zurück zum Zitat Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual targeting of acute leukemia and supporting Niche by CXCR4-directed theranostics. Theranostics. 2018;8(2):369–83.CrossRefPubMedPubMedCentral Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual targeting of acute leukemia and supporting Niche by CXCR4-directed theranostics. Theranostics. 2018;8(2):369–83.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, et al. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Invest Radiol. 2018;53(7):403–8.CrossRefPubMed Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, et al. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Invest Radiol. 2018;53(7):403–8.CrossRefPubMed
23.
Zurück zum Zitat Juntikka T, Vaittinen S, Vahlberg T, Jyrkkiö S, Minn H. Somatostatin receptors and chemokine receptor cxcr4 in lymphomas: a histopathological review of six lymphoma subtypes. Front Oncol. 2021;11: 710900.CrossRefPubMedPubMedCentral Juntikka T, Vaittinen S, Vahlberg T, Jyrkkiö S, Minn H. Somatostatin receptors and chemokine receptor cxcr4 in lymphomas: a histopathological review of six lymphoma subtypes. Front Oncol. 2021;11: 710900.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Zhang YA, Yang X, Yao J, Ren Y, Liu P. Identification of CXCR4 upregulation in diffuse large B-cell lymphoma associated with prognostic significance and clinicopathological characteristics. Dis Markers. 2022;2022:3276925.PubMedPubMedCentral Zhang YA, Yang X, Yao J, Ren Y, Liu P. Identification of CXCR4 upregulation in diffuse large B-cell lymphoma associated with prognostic significance and clinicopathological characteristics. Dis Markers. 2022;2022:3276925.PubMedPubMedCentral
25.
Zurück zum Zitat Danis J, Kelemen E, Rajan N, Nagy N, Széll M, Ádám É. TRAF3 and NBR1 both influence the effect of the disease-causing CYLD(Arg936X) mutation on NF-κB activity. Exp Dermatol. 2021;30(11):1705–10.CrossRefPubMed Danis J, Kelemen E, Rajan N, Nagy N, Széll M, Ádám É. TRAF3 and NBR1 both influence the effect of the disease-causing CYLD(Arg936X) mutation on NF-κB activity. Exp Dermatol. 2021;30(11):1705–10.CrossRefPubMed
26.
Zurück zum Zitat Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, et al. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021;5(19):3776–88.CrossRefPubMedPubMedCentral Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, et al. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021;5(19):3776–88.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Perez-Chacon G, Adrados M, Vallejo-Cremades MT, Lefebvre S, Reed JC, Zapata JM. Dysregulated TRAF3 and BCL2 expression promotes multiple classes of mature Non-hodgkin B cell lymphoma in Mice. Front Immunol. 201;9:3114. Perez-Chacon G, Adrados M, Vallejo-Cremades MT, Lefebvre S, Reed JC, Zapata JM. Dysregulated TRAF3 and BCL2 expression promotes multiple classes of mature Non-hodgkin B cell lymphoma in Mice. Front Immunol. 201;9:3114.
28.
Zurück zum Zitat Pérez-Carretero C, Hernández-Sánchez M, González T, Quijada-Álamo M, Martín-Izquierdo M, Santos-Mínguez S, et al. TRAF3 alterations are frequent in del-3’IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022;97(7):903–14.CrossRefPubMed Pérez-Carretero C, Hernández-Sánchez M, González T, Quijada-Álamo M, Martín-Izquierdo M, Santos-Mínguez S, et al. TRAF3 alterations are frequent in del-3’IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022;97(7):903–14.CrossRefPubMed
Metadaten
Titel
First reported case of splenic diffuse red pulp small B-cell lymphoma with novel mutations in CXCR4 and TRAF3 genes
verfasst von
Suying Zheng
Ling Lin
Jing Jin
Fang Liu
Jianguo Wei
Yi Feng
Yaping Zhang
Hongqiang Luo
Jiayue Qin
Weiying Feng
Publikationsdatum
19.03.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 3/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03581-3

Weitere Artikel der Ausgabe 3/2023

International Journal of Hematology 3/2023 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.